Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b multiple ascending dose escalation study to evaluate the safety and
tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.